证券代码：688526 证券简称：科前生物 公告编号：2024-056 武汉科前生物股份有限公司 持股 5%以上股东、监事减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东、监事持股的基本情况 本次减持计划实施前，武汉科前生物股份有限公司（以下简称"公司"）持 股 5%以上股东、监事叶长发先生直接持有公司股份 27,506,141 股，占公司总股 本的 5.90%，股份来源为公司首次公开发行前取得的股份，该部分股份已于 2023 年 9 月 22 日解除限售并上市流通。 减持计划的实施结果情况 公司于 2024 年 6 月 15 日在上海证券交易所网站披露了《武汉科前生物股份 有限公司持股 5%以上股东、监事减持股份计划公告》（公告编号:2024-035），公 司持股 5%以上股东、监事叶长发先生因自身资金需求拟通过集中竞价交易与大 宗交易相结合的方式合计减持不超过 6,876,535 股，即不超过公司总股本的 1.48%。 2024 年 10 月 7 日，公司收到叶长发先 ...

证券代码：688526 证券简称：科前生物 公告编号：2024-057 武汉科前生物股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购股份情况公告如下： 截至 2024 年 9 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购公司股份 1,903,866 股，占公司总股本 466,128,056 股的比例为 0.4084%，回购成交的最高价为 18.90 元/股，最低价为 13.48 元/股，支付的资金 总额为人民币 31,618,428.15 元（不含印花税、交易佣金等交易费用）。 本次回购股份进展符合法律法规的规定及公司回购股份方案。 三、 其他事项 重要内容提示： | 回购方案首次披露日 | 2024/2/3，由实际控制人何启盖先生、方六荣 女士 ...

证券代码：688526 证券简称：科前生物 武汉科前生物股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------| | | | | | 投资者关系活动类别 | ☐ 特定对象调研 | ☐ 分析师会议 | | | ☐ 媒体采访 | 业绩说明会 | | | ☐ 新闻发布会 | ☐ 路演活动 | | | ☐ 现场参观 | | | | ☐ 其他（请文字说明其他活动内容） | | | 参与单位名称及人员 姓名 | 线上参与公司 2024 | 年半年度业绩说明会 | | 时间 | 2024年09 月27日 | 10:00-11:00 | | 地点 | 价值在线（ | https://www.ir-online.cn/ ）网络互动 | | | 董事长、总经理 | 陈慕琳 ...

证券代码：688526 证券简称：科前生物 公告编号：2024-055 截至本公告披露日，何启盖先生持有公司 7.12％的股份，吴斌先 生持有公司 7.12％的股份，方六荣女士持有公司 7.12％的股份，吴 美洲先生持有公司 6.13％的股份。四人合计持有公司 27.48％的股份， 为公司实际控制人。何启盖先生、方六荣女士、吴美洲先生为公司董 事，吴斌先生为公司监事会主席。 上述各方于 2023 年 9 月 22 日签订了原《一致行动人协议》，约 武汉科前生物股份有限公司 关于实际控制人续签一致行动人协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 武汉科前生物股份有限公司（以下简称"公司"）于 2024 年 9 月 20 日收到公司实际控制人何启盖先生、吴斌先生、方六荣女士、吴美 洲先生关于续签《一致行动人协议》的通知。鉴于各方在 2023 年 9 月 22 日签署的《一致行动人协议》（以下简称"原《一致行动人协 议》"）即将到期，为完善公司治理，保证公司经营的连续性和稳定 性，实现对公司实质且有效的控制，各 ...

证券代码：688526 证券简称：科前生物 公告编号：2024-054 武汉科前生物股份有限公司 关于召开2024年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 武汉科前生物股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了《武汉科 前生物股份有限公司 2024 年半年度报告》及《武汉科前生物股份有 限公司 2024 年半年度报告摘要》。为便于广大投资者更加全面深入 地了解公司 2024 年半年度经营业绩、发展战略等情况，公司定于 2024 年 09 月 27 日（星期五）10:00-11:00 在"价值在线"（www.ir- 会议召开时间：2024 年 09 月 27 日（星期五）上午 10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会议问题征集：投资者可于 2024 年 09 月 27 日前访问网址 https://eseb.cn/1hUYaZ ...

Investment Rating - The investment rating for the company is "Outperform the Market" [3][7] Core Views - The company's main business profitability has declined, with a significant drop in revenue and net profit in the first half of 2024 due to a sluggish breeding market and intensified industry competition [4][6] - The revenue from pig vaccines has decreased, while the company continues to invest in R&D, leading to the launch of new products like the cat trivalent vaccine [5][6] - The report anticipates a recovery in the breeding market, which could benefit the demand for animal health products, particularly pig vaccines [6][7] Summary by Sections Financial Performance - In H1 2024, the company achieved revenue of 401 million yuan, down 24.69% year-on-year, with Q2 revenue at 196 million yuan, a decrease of 4.56% quarter-on-quarter and 22.49% year-on-year [4][6] - The net profit attributable to the parent company for H1 2024 was 153 million yuan, a decline of 36.19% year-on-year, with Q2 net profit at 65 million yuan, down 25.05% quarter-on-quarter and 36.91% year-on-year [4][6] Business Segments - Revenue from pig vaccines in H1 2024 was 351 million yuan, down 28.04% year-on-year, with a gross margin of 66.69%, a decrease of 7.59 percentage points compared to the full year of 2023 [5][6] - Revenue from poultry vaccines increased by 13.86% year-on-year to 8.5148 million yuan, but the gross margin was negative at -31.46% [5][6] - Other business revenue grew by 33.48% year-on-year to 22.7963 million yuan, with a gross margin of 55.80% [5][6] R&D and Product Development - The company increased R&D investment to 40.3594 million yuan in H1 2024, leading to the registration of new veterinary drugs and the launch of the cat trivalent vaccine [5][6] - The report highlights the potential for continued product development and market expansion due to solid R&D foundations [6][7] Market Outlook - The report suggests that the pig cycle is entering a recovery phase, which could lead to increased demand for high-quality pig vaccines as breeding profits improve [6][7] - The company is positioned to benefit from the recovery in pig prices, which is expected to drive revenue growth [6][7] Profitability and Valuation - The forecast for net profit for 2024-2026 has been revised down to 420 million, 490 million, and 500 million yuan respectively, with corresponding EPS of 0.90, 1.05, and 1.08 [7][9] - The current price-to-earnings ratio is projected to be 14, 12, and 12 times for the years 2024, 2025, and 2026 respectively [7][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4]. Core Views - The company's operating performance is under short-term pressure, but R&D investments are entering a harvest period [2]. - In H1 2024, the company reported a revenue of 401 million yuan, a year-on-year decrease of 24.69%, and a net profit attributable to the parent company of 153 million yuan, down 36.19% year-on-year [2]. - The sales revenue from the pig vaccine business decreased by 28.04% year-on-year, while the poultry vaccine business saw a growth of 13.77% [2]. - The company has made progress in R&D, obtaining four new veterinary drug registration certificates [2]. Summary by Sections Financial Performance - In H1 2024, the company achieved a revenue of 401 million yuan, down 24.69% year-on-year, and a net profit of 153 million yuan, down 36.19% year-on-year [2]. - For Q2 2024, revenue was 196 million yuan, a decrease of 22.49% year-on-year, with a net profit of 65 million yuan, down 36.91% year-on-year [2]. - The company’s gross margin decreased by 10.34 percentage points due to increased competition in the industry [2]. R&D Progress - The company has received registration certificates for four new veterinary drugs, including a new inactivated vaccine for pig coronavirus [2]. - Two products have completed re-examination tests, and there are ongoing re-examinations for other vaccines [2]. Market Confidence - The company initiated a share repurchase plan in February 2024, repurchasing 1.7845 million shares for a total of 30 million yuan by the end of June [2]. - The repurchased shares are intended for employee stock ownership plans or equity incentives [2]. Earnings Forecast - The revenue forecast for 2024-2026 is adjusted to 975 million, 1.081 billion, and 1.240 billion yuan, with year-on-year changes of -8.41%, +10.96%, and +14.67% respectively [2]. - The net profit forecast for the same period is 361 million, 403 million, and 459 million yuan, with year-on-year changes of -8.77%, +11.66%, and +13.92% respectively [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company is experiencing short-term operational pressure but is expected to see performance recovery in the second half of 2024 due to high pig prices [4] - The company reported a revenue of 401 million yuan in H1 2024, a decrease of 24.69% year-on-year, and a net profit attributable to shareholders of 153 million yuan, down 36.19% year-on-year [4] - The company maintains high R&D investment and continues to launch new products, which is expected to support future growth [6] Financial Performance Summary - H1 2024 revenue: 401 million yuan (-24.69% YoY), Q2 revenue: 196 million yuan (-22.49% YoY) [4] - H1 2024 net profit: 153 million yuan (-36.19% YoY), Q2 net profit: 65 million yuan (-36.91% YoY) [4] - The company’s expense ratios for sales, management, and finance in H1 2024 were 14.01%, 6.34%, and -7.56%, respectively [4] - Revised profit forecasts for 2024-2026: 324 million yuan, 399 million yuan, and 476 million yuan, respectively [4] Product Segment Performance - Revenue from pig vaccines in H1 2024 was 351 million yuan (-28.04%), accounting for 87.59% of total revenue [5] - Revenue from poultry vaccines increased by 13.86% to 9 million yuan, while revenue from pet vaccines grew by 33.48% to 23 million yuan [5] R&D and Innovation - R&D expenses in H1 2024 were 40 million yuan (-7.88%), representing 10.08% of revenue [6] - The company is focusing on developing new vaccine platforms and has obtained four new veterinary drug registration certificates [6]

Financial Performance - The company reported a total revenue of 100 million RMB for the first half of 2024, representing a 20% increase compared to the same period last year[8]. - The company's operating revenue for the first half of 2024 was ¥400,510,475.63, a decrease of 24.69% compared to the same period last year[13]. - Net profit attributable to shareholders decreased by 36.19% year-on-year, amounting to ¥152,608,566.88[14]. - The basic earnings per share fell by 35.29% to ¥0.33, while the diluted earnings per share also decreased by the same percentage[14]. - The net cash flow from operating activities was ¥161,566,468.41, down 27.05% from the previous year[13]. - The total comprehensive income for the first half of 2024 was CNY 156,612,017.42, compared to CNY 238,976,717.50 in the same period of 2023[160]. - The company achieved operating revenue of CNY 400.51 million, a year-on-year decrease of 24.69%[80]. - The net profit attributable to the parent company was CNY 152.61 million, down 36.19% year-on-year[80]. Research and Development - The company has invested over 270 million yuan in R&D over the past three years, with 75 specific R&D projects initiated in 2024[43]. - The total R&D expenditure for the reporting period was approximately 40.36 million yuan, a decrease of 7.88% compared to the previous year[45]. - R&D expenditure accounted for 10.08% of total revenue, an increase of 1.84 percentage points year-on-year[45]. - The company has established multiple advanced technology platforms, including CRISPR/Cas9 gene editing and mRNA vaccine development, to drive innovation in product development[39][40]. - The company has developed a recombinant protein high-efficiency expression technology platform, achieving significant results in vaccine development for various diseases[40]. - The company is actively pursuing the development of multi-valent vaccines using advanced platforms, enhancing its capabilities in disease prevention[41]. - The company has established a high-level R&D center recognized by multiple government bodies, including the designation as a National Enterprise Technology Center in December 2019[57]. Product Development and Innovation - New product development includes the launch of two innovative biological products, projected to contribute an additional 30 million RMB in revenue by the end of 2024[8]. - The company is focused on developing high-quality and high-value-added animal biological products, including poultry and pet vaccines[19]. - The company has developed a range of inactivated vaccines for swine, including those for porcine reproductive and respiratory syndrome and porcine circovirus type 2, with high antigen content and effective immune response[22]. - The company has introduced advanced production techniques for its vaccines, ensuring high antigen content and safety[24]. - The company has developed innovative vaccines for other animal diseases, including the first officially approved dual inactivated vaccine for porcine epidemic diarrhea, suitable for controlling variant strains of the virus[63]. - The company has established a specialized technical service team to drive sales through technology and service, aligning with its marketing strategy[26]. Market Position and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[8]. - The company ranks second in the domestic non-national compulsory immunization veterinary biological products market and first in the non-national compulsory immunization pig biological products market from 2018 to 2023[36]. - The market share for the company's key products in 2023 includes 34.38% for the pig pseudorabies vaccine, 38.74% for the pig parvovirus vaccine, and 49.38% for the pig gastrointestinal and diarrhea dual vaccine, all ranking first[37]. - The company employs a "sales-driven production + safety stock" model, ensuring production plans align with sales targets and seasonal disease prevention needs[29]. - The company has established a market demand-oriented and technology innovation-driven model, leveraging a deep sales network to gather epidemiological information and continuously develop new products, which has led to stable profitability and high gross margins[27]. Financial Position and Assets - The company maintains a strong cash position with 50 million RMB in cash reserves, ensuring liquidity for future investments[8]. - The company's total assets decreased by 4.29% to ¥4,470,855,977.57 compared to the end of the previous year[13]. - The company has overseas assets totaling CNY 101.55 million, accounting for 2.27% of total assets[84]. - The company reported a total current assets of approximately ¥2.57 billion as of June 30, 2024, compared to ¥2.57 billion as of December 31, 2023, indicating a slight increase[152]. - Cash and cash equivalents increased to ¥688.95 million from ¥581.74 million, reflecting a growth of approximately 18.4%[152]. Risks and Challenges - The company has identified potential risks, including regulatory changes that could impact operations, but no substantial risks were reported during the period[3]. - The company faces risks related to technological innovation, including long development cycles and high investment costs, which may impact its competitive position if competitors launch products first[70]. - The company is exposed to market competition risks as the number of domestic veterinary biological product companies increases, potentially affecting its profitability[73]. - The company faces risks related to the expiration of necessary administrative licenses and product approval numbers, which could impact its ability to continue production and sales[72]. - The company is at risk of product quality issues that could negatively affect its reputation and lead to regulatory penalties, despite having a complete quality management system in place[72]. Environmental and Social Responsibility - The company invested 765,900 RMB in environmental protection during the reporting period[96]. - The total wastewater discharge was 1.44 tons, with no exceedance of discharge standards[96]. - The company has implemented measures to reduce carbon emissions, including using electric forklifts and energy-saving light bulbs[105]. - The company has established a comprehensive emergency response plan for environmental incidents, which was filed in November 2021[100]. - The company has achieved compliance with environmental monitoring requirements, with all pollutants meeting discharge standards[101]. Corporate Governance and Compliance - The board of directors has confirmed that there are no non-operational fund usages by controlling shareholders[3]. - The company emphasizes its commitment to transparency and has ensured that all financial reports are accurate and complete[2]. - The company has committed to a profit distribution policy, which is also a long-term commitment[108]. - The company has established measures to ensure compliance with commitments made in the prospectus, including public disclosure of any failures to fulfill these commitments[21]. - The company has committed to not engaging in any business that competes with Kexin Bio, both domestically and internationally[123].

二、监事会会议审议情况 经与会监事审议，作出决议如下： （一）审议通过《关于公司<2024 年半年度报告>及其摘要的议 案》 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 证券代码：688526 证券简称：科前生物 公告编号：2024-051 武汉科前生物股份有限公司 第四届监事会第四次会议决议公告 武汉科前生物股份有限公司（下称"公司"）于 2024 年 8 月 29 日以通讯与现场相结合的形式召开第四届监事会第四次会议（以下简 称"本次会议"）。本次会议通知于 2024 年 8 月 19 日以邮件、电话 的方式向各位监事发出，本次会议由监事会主席吴斌先生主持，本次 会议应参与表决监事 3人，实际参与表决监事3人。本次会议的召集、 召开程序均符合《公司法》《证券法》等法律、法规和规范性文件以 及《公司章程》的规定。 武汉科前生物股份有限公司监事会 监事会认为：2024 年半年度报告的编制和审议程序符合相关法 律法规、《公司章程》及公司管理制度的有关规定。报告的内容与格 式符合有关规定，公允地反 ...